ZEAGRA Tablet

ក្រុមហ៊ុនផលិតឱសថ:

 

ZEE LABORATORIES, India

ក្រុមហ៊ុនចែកចាយឱសថនៅប្រទេសកម្ពុជា:

 

Z.H.C.L.

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • អន្តរប្រតិកម្ម
  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
  • ការប្រុងប្រយ័ត្នជាពិសេស
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

    1. ZEAGRA Tablet 25mg:

    Sildenafil 25mg

    2. ZEAGRA Tablet 50mg:

    Sildenafil 50mg

    3. ZEAGRA Tablet 100mg:

    Sildenafil 100mg

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    ZEAGRA is indicated for the treatment of Erectile Dysfunction(ED).

    Dosage& Administration

    For most patients, the recommended dose is 50mg taken, as needed, approximately 1 hour before sexual activity. However, ZEAGRA may be taken anywhere from 4 hours to 30 minutes before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100mg or decreased to 25mg. The maximum recommended dosing frequently is once per day.

  • ហាមប្រើ

    Consistent with its known effects on the nitric oxide/cGMP pathway, ZEAGRA was shown to potentiate the hypotensive effects on nitrates and its administration to patients who are using organics nitrates, either regularly and/or intermittently, in any form is therefore contraindicated, ZEAGRA is contraindicated in patients with a known hypersensitivity to any component of the tablet.

  • ផលរំខាន

    There is a potential for cardiac risk of sexual activity in patients with pre-existing cardiovascular disease. Therefore, treatments for erectile dysfunction, including ZEAGRA should not generally used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status.

    There is no controlled clinical data on the safety or efficacy of ZEAGRA in the following groups, if prescribed, this should be done with caution:

    - Patients who have suffered a myocardial infarction, stroke of life-threatening arrhythmia within the last 6 months.

    - Patients with resting hypotension (BP<90/50) or hypertension (BP>170/110).

    - Patients with cardiac failure or coronary artery disease causing unstable angina.

    - Patients with retinitis pigmented.

  • អន្តរប្រតិកម្ម

    A reduction in sildenafil clearance occurs when it was co-administered with CYP3A4 inhibitors, such as ketoconazole, itraconazole, erythromycin or cimetidine. It can be expected that concomitant administration of CYP3A4 inducers, such as rifampin will decrease the plasma levels of sildenafil.

    Co-administration with HIV protease inhibitors ritonavir/saquinavir results in increase in sildenafil Cmax&Plasma AUC.

  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន

    ZEAGRA is not indicated for use in new borns, children or women.

  • ការប្រុងប្រយ័ត្នជាពិសេស

    Commonly reported adverse events of patients treated with sildenafil include the following:

    headache(16%), flushing(10%), dyspepsia(7%), nasal congestion(4%), abnormal vision(3%), diarrhea(3%), dizziness(2%), resh(2%).

    In studies with healthy volunteers of single doses up to 800mg adverse events were similar to those seen at lower doses but incidence rates were increased.

  • សកម្មភាពឱសថ

    An oral therapy for erectile dysfunction (ED), is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specified Phosphodiesterase type 5 (PDE5).

    Sildenafil citrate is designed chemically as 1-{(3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl) sulfonyl}-4-methylpiperazine citrate and has a molecular weight of 666.7.

    The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. Nitric Oxide (NO) then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the courpus cavernosum and allowing inflow of blood. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of nitric oxida (NO) by inhibiting phos-phodiesterase type 5 (PDE5), which is responsible for degeneration of cGMP in the corpus cavernosum.

    When sexual stimulation cause local release of nitric oxide (NO),inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, Sildenafil at recommended doses has no effect in the absence of sexual stimulation.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp